The FDA approved Agios’ and Celgene’s enasidenib for acute myeloid leukaemia (AML),
validating metabolism-modulating drugs as a means of killing cancer cells.

Para acessar a publicação na íntegra clique  aqui

Fonte: Nature Reviews Drug Discovery VOLUME 16 | SEPTEMBER 2017 | 593